Business
Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision
JACKSONVILLE, Fla., April 10, 2026--Johnson & Johnson showcases new clinical data for TECNIS PureSee IOL demonstrating excellent contrast sensitivity and extended range of vision
About this update from Johnson & Johnson
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2690,"height":510,"url":"https://media.zenfs.com/en/business-wire.com/8353249af999ce5e3d5a6515004d42fc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xU8WFTqAtlqBruZOCdhhDQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE4Mg--/https://media.zenfs.com/en/business-wire.com/8353249af999ce5e3d5a6515004d42fc","width":960,"height":182},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/GbLNk8m1dmLNgqupZ.0aTA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00NTY-/https://media.zenfs.com/en/business-wire.com/8353249af999ce5e3d5a6515004d42fc","width":1200,"height":228}},"lazy":false},{"type":"text","content":"Robust clinical data, spans two major studies across U.S., Europe and Asia Pacific","length":82,"tagName":"p"},{"type":"text","content":"Data reveals TECNIS PureSee IOL achieved exceptional distance and intermediate vision, low bothersome visual symptoms, high tolerance to post-op refractive errors","length":162,"tagName":"p"},{"type":"text","content":"High patient satisfaction results with TECNIS PureSee IOL","length":57,"tagName":"p"},{"type":"text","content":"JACKSONVILLE, Fla., April 10, 2026--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present data from two major studies supporting the performance of its recently FDA-approved TECNIS PureSee intraocular lens (IOL) at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, April 10-13 in Washington, DC. TECNIS PureSee IOL is J&J’s next-generation Extended Depth of Focus (EDOF) IOL, which demonstrates excellent clinical outcomes and provides significantly improved range of vision* and reduced visual symptoms compared to a monofocal IOL.1^","length":583,"tagName":"p"},{"type":"text","content":""The data presented at ASCRS 2026 confirms that TECNIS PureSee IOL provides patients with high contrast sensitivity and visual acuity across distances, with low levels of visual disturbances," said Paul Lisenby, Global Head of Research and Development, Vision, Johnson & Johnson. "This evidence underscores our commitment to advancing innovation through rigorous clinical research—extending the range of vision for our patients and reinforcing surgeon confidence."","length":488,"tagName":"p"},{"type":"text","conten...